Navigation Links
Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
Date:2/26/2009

al devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, goodwill impairment charges and litigation matters. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many o
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
2. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
3. Boston Scientific Acquires Labcoat Limited
4. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
5. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
6. Boston Scientific to Participate in Piper Jaffray Health Care Conference
7. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
8. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
9. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
10. InterMune to Present at Deutsche Bank Biotech Boston Confab
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... BOSTON , June 17, 2013 ... $127 billion by 2018, accounting for nearly 16 percent of ... Orphan Drug Report 2013 from Evaluate .   ... to this growing segment of the pharmaceutical industry, Evaluate has ... in-depth, fact-based orphan drug analysis with data fields for integrated ...
(Date:6/17/2013)... 2013 With the huge success of CMO ... Chief Medical Officer Summit for Emerging Life Science Companies on ... in San Francisco on November 4-5, 2013 at the Marines ... West Coast Chief Medical Officers at biotechs have their own ... Director of MPM Capital. Valerie Bowling, Executive Director of The ...
(Date:6/17/2013)... Z Trim Holdings, Inc. (OTC Markets: ... ingredients to a variety of industries, today announced ... application at this year,s annual Institute of Food ... , July 13-16. The Company will demonstrate how ... in meat products thereby helping manufacturers lower costs ...
(Date:6/17/2013)... , June 17, 2013 ... ) has announced the addition of the ... - by Formulations [Liposomes, Microspheres, & Nanoparticles], ... Pen, Needle Free & Auto Injectors] & ... their offering. ,      (Logo: ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... adds new line of heart disease and diabetes ... 20 Atherotech, Inc. ... Cholesterol Test in booth #912 at Internal Medicine ... College of Physicians (ACP). The conference takes place ...
... Proof of Mechanism of a Potential Oral Antagonist for ... Amira Pharmaceuticals, Inc., announced today the initiation of ... discovered oral drug candidate for the treatment and control ... acid pathway.AM211 is an oral, selective antagonist of the ...
... Data are New Releases for the Company Building ... Discoveries --DENVER, April 20 DXL625 ... antibodies in their ability to attach and deplete ... research conducted at InNexus Biotechnology Inc. (Toronto Stock ...
Cached Biology Technology:Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 2Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 3Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:6/14/2013)... the only ones tending their gardens. , At the ... ants cultivate thriving communities of fungi and bacteria using ... are a source of food and shelter for the ... biofuel production. , "We are interested in the whole ... goes in and is converted to energy for the ...
(Date:6/14/2013)... By identifying a protein that acts as a ... have solved the mystery of why some infants are ... and major deformities of the skin and limbs, while ... little or no sign of the illness, called EEC. ... It is rare in its full-blown form, although individual ...
(Date:6/14/2013)... Data presented at EULAR 2013, the Annual Congress of ... biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). ... and UH-RA.21 were investigated; as a group they ... both early and seronegative disease, with 36% of ... patients testing positive. , RA is a chronic ...
Breaking Biology News(10 mins):Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3
... The best place to enjoy a breath of fresh air may ... A team of graduating seniors has created a system for public ... lead to tuberculosis (TB), flu and pneumonia. The CityBusters ... Chen, all seniors have installed a $500 device on a ...
... significantly slow the pace of climate change with practical ... bringing successful Western technologies to the developing world, according ... Foreign Affairs . For the last two ... to make progress. Part of the problem, the ...
... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... its first quarter ended March 31, 2012.  Revenues ... of 10% compared to $6.4 million in the same quarter last ... million, or $0.05 per diluted share. These results compared to net ...
Cached Biology News:College students work to sterilize air, kill pathogens on buses 2College students work to sterilize air, kill pathogens on buses 3College students work to sterilize air, kill pathogens on buses 4UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 2UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 3UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 4Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: